Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Equity (2024 - 2026)

Prelude Therapeutics' Return on Equity history spans 3 years, with the latest figure at 0.01% for Q1 2026.

  • On a quarterly basis, Return on Equity changed 0.0% to 0.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.01%, a 0.0% change, with the full-year FY2025 number at 0.01%, changed 0.0% from a year prior.
  • Return on Equity hit 0.01% in Q1 2026 for Prelude Therapeutics, up from 0.02% in the prior quarter.
  • Over the last five years, Return on Equity for PRLD hit a ceiling of 0.01% in Q3 2024 and a floor of 0.02% in Q3 2025.
  • Historically, Return on Equity has averaged 0.01% across 3 years, with a median of 0.01% in 2026.
  • Biggest five-year swings in Return on Equity: decreased -1bps in 2025 and later changed 0bps in 2026.
  • Tracing PRLD's Return on Equity over 3 years: stood at 0.01% in 2024, then plummeted by -69bps to 0.02% in 2025, then increased by 21bps to 0.01% in 2026.
  • Business Quant data shows Return on Equity for PRLD at 0.01% in Q1 2026, 0.02% in Q4 2025, and 0.02% in Q3 2025.